The following is an excerpt from a 10-Q SEC Filing, filed by LIGAND PHARMACEUTICALS INC on 5/7/2004.
-- Use Sections To Navigate Through The Document --
FORM 10-Q
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BALANCE SHEET
INCOME STATEMENT
CASH FLOW
Notes to Consolidated Financial Statements
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
ITEM 4. CONTROLS AND PROCEDURES
PART II. OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES, USE OF PROCEEDS AND ISSUER ...
ITEM 6. (A) EXHIBITS
SIGNATURE
EXHIBIT 10
EXHIBIT 10
EXHIBIT 10
EXHIBIT 10
EXHIBIT 10
EXHIBIT 31
CHIEF EXECUTIVE OFFICER CERTIFICATION
EXHIBIT 31
CHIEF FINANCIAL OFFICER CERTIFICATION
EXHIBIT 32
CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER
EXHIBIT 32
CERTIFICATION BY CHIEF FINANCIAL OFFICER
LIGAND PHARMACEUTICALS INC - 10-Q - 20040507 - BALANCE_SHEET
LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31,
December
31,
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
65,558
$
59,030
Short-term investments; $9,247 and $9,204 restricted
at March 31, 2004 and
31,625
40,004
Accounts receivable, net (Note 2)
14,185
19,051
Inventories
9,770
8,262
Other current assets
3,764
3,810
Total current assets
124,902
130,157
Restricted investments
1,656
1,656
Property and equipment, net
23,620
23,501
Aquired technology and product rights, net
135,189
137,857
Other assets
8,822
8,084
Total assets
$
294,189
$
301,255
LIABILITIES AND
STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
16,866
$
18,691
Accrued liabilites
35,304
30,315
Current portion of deferred revenue
2,346
2,564
Current portion of equipment financing obligations
2,439
2,184
Current portion of long-term debt
303
295
Total current liabilities
57,258
54,049
Long-term debt
167,328
167,408
Long-term portion of deferred revenue
2,198
2,275
Long-term portion of equipment financing
obligations
3,518
2,644
Other long-term liabilities
3,516
4,151
Total liabilities
233,818
230,527
Commitments and contingencies (Note 6)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 5,000,000
shares authorized; none issued
—
—
Common
stock, par value $0.001; 130,000,000 shares authorized, 73,532,889 and 73,264,785 shares issued at March 31, 2004 and
December 31, 2003, respectively
74
73
Additional paid-in capital
730,178
727,410
Accumulated other comprehensive loss
(53
)
(66
)
Accumulated deficit
(668,917
)
(655,778
)
61,282
71,639
Treasury stock, at cost; 73,842 shares
(911
)
(911
)
Total stockholders’ equity
60,371
70,728
$
294,189
$
301,255
Next Section
Previous Section